About Clinical Research
Study #50223

This clinical research study will be evaluating the concentration of two medications used to treat migraines, in breast milk.

Are You a Good Fit?

Female/Mother

Feeds infant breast milk at least 50% of the time

BMI between 18 and 40 kg/m2

Had a normal pregnancy (gestation of 37-42 weeks) with no clinically significant complications

1 to 6 months post-partum

  • Receive up to $1,550 for your participation in this study
Mom lifting baby and smiling

What are the Time Requirements?

This study will consist of 2 1/2-day inhouse stay with 2 follow-up phone calls. Study dates are as follows:

How Much: $1,550

BMI Calculator

BMI Calculator Simple

Weight

Unit of measurement*
cm
kg
ft
in
lbs

BMI

Referral Program

Do not forget our REFERRAL PROGRAM. Earn at least $200 for every new participant you refer who completes a study.*

*No referral bonuses are paid out for outpatient vaccine studies.

All study dates are tentative and subject to change.

We will update the clinical research studies list weekly. Be sure to check with us either by calling or going online. Call (417) 831-2048 or visit 417studies.com more information. You can also visit the Screening and Recruitment Center located at 2025 W. Sunshine Street, L-109. Office hours are Monday through Friday from 8 a.m. to 5 p.m.
  • Females, Non-Childbearing Potential
    • Females do not need to use birth control during or following study drug treatment if considered
      of non-childbearing potential due to the following: permanent sterility due to a hysterectomy,
      bilateral salpingectomy, bilateral oophorectomy
  • Females, of Childbearing Potential
    • Females of childbearing potential consent to abide by contraception requirements.
    • Females of childbearing potential must avoid pregnancy while taking study drug(s) and for at least 30 days after the last dose of study drug.
  • Females must commit to one of the following methods of birth control:
    • Combined (estrogen and progestogen containing) hormonal birth control (oral, intravaginal, injectable, transdermal) associated with inhibition of ovulation initiated at least 30 days prior to initial dose administration
    • Progestogen-only hormonal birth control (oral, injectable, implantable) associated with inhibition of ovulation-initiated at least 30 days prior to initial dose administration
    • bilateral tubal occlusion/ligation
    • intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Vasectomized partner (provided the partner has received medical confirmation of the surgical success of the vasectomy, and is the sole sexual partner of the trial participant)
    • Practice true abstinence: the usual and preferred lifestyle of the subject does not include heterosexual intercourse (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable).
    • Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, initiated at least 30 days prior to initial dose administration.
    • Male or female condom with or without spermicide.
    • Cap, diaphragm or sponge with spermicide.
    • A combination of male condom with cap, diaphragm or sponge with spermicide (double barrier method).
    • Female who is not considering becoming pregnant or donating eggs during the study or for approximately 30 days after the last dose of study drug.

If you have previously submitted an application, call 417-831-2048 to enroll. Or click on the button below to submit your application now.

Apply Online Now